GSK AWP settlement
Executive Summary
GlaxoSmithKline settles average wholesale price class action litigation for $70 mil., the company announces Aug. 10. Plaintiffs alleged that GSK inflated certain AWPs - primarily for antiemetics Zofran and Kytril. The settlement, which covers all claims filed in Boston federal court, resolves most of the AWP litigation pending against GSK, company says. GSK reached civil settlements with six state attorneys general as part of a September settlement with the Department of Justice over Zofran and Kytril pricing (1"The Pink Sheet" Sept. 26, 2005, p. 6). Reportedly, there are more than a dozen remaining defendants involved in the AWP litigation, including AstraZeneca and Bristol-Myers Squibb...